logo

Zynerba Pharmaceuticals, Inc. (ZYNE)



Trade ZYNE now with
  Date
  Headline
9/18/2019 6:35:15 AM Zynerba Pharma Announces Positive Top Line Data From BELIEVE 1 Open Label Phase 2 Study Of Zygel
7/1/2019 7:47:15 AM Zynerba To Be Added To U.S. All-cap Russell 3000, Small-cap Russell 2000 Indexes
6/11/2019 7:12:21 AM Zynerba Pharmaceuticals Receives New U.S. Patent For Autism Spectrum Disorder With Cannabidiol
2/26/2019 7:25:11 AM Zynerba Pharma Gets New U.S. Patent For Fragile X Syndrome With Cannabidiol
1/22/2019 8:47:24 AM SCYNEXIS Appointms Armando Anido To Its Board
11/8/2018 6:55:16 AM Zynerba Pharma Q3 Loss Per Share $0.47 Vs Loss $0.63 Last Year
8/2/2018 6:54:42 AM Zynerba Q2 Net Loss $12.0 Mln Or $0.89/Shr
7/20/2018 9:11:31 AM Zynerba Pharma Prices Underwritten Public Offering Of 4.06 Mln Shares At $8.00/shr
7/19/2018 4:08:24 PM Zynerba Pharmaceuticals Announces Proposed Public Offering Of Common Stock
7/12/2018 7:33:40 AM Zynerba Pharma Announces New FAB-C Phase 2 Open-Label Data In Patients With Fragile X Syndrome
7/9/2018 6:56:27 AM Zynerba Begins CONNECT-FX, A Pivotal Clinical Trial Of ZYN002 In Fragile X Syndrome
7/5/2018 4:23:22 PM Zynerba's Marijuana Flop
  
 
>